Novocure Optune Pax Receives CE Mark for Pancreatic Cancer
Novocure's Optune Pax device received a CE Mark for locally advanced pancreatic cancer supported by significant overall survival improvements in the PANOVA-3 trial. This regulatory milestone expands the device's market reach and addresses the critical need for effective therapies in pancreatic cancer treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day